 Evidence platelet-activating factor late-phase mediator chronic pancreatitis rat role platelet-activating factor PAF mediator pancreatic inflammation rat pancreatic duct ligation model obstructive pancreatitis Pancreatic generation PAF bioassay ie serotonin secretion various times induction inflammation Tissue levels PAF normal pancreas pg/g PAF detectable initial hours pancreatitis time inflammatory reaction acute period maximal serum amylase release development interstitial edema substantial increase pancreatic PAF levels times control levels days duct ligation late-phase response interval similar situation characteristic chronic pancreatitis parenchymal atrophy fibrosis pancreatic insufficiency evolve week duct ligation PAF levels evaluation effects PAF antagonists pancreatic lesions Evan blue extravasation pancreatic myeloperoxidase MPO activity acid phosphatase activity peritoneal lavage fluid treatment pancreatic damage inflammation Long-term vivo administration exogenous PAF micrograms/kg/hr days reduction thymidine uptake release pancreatic acini vitro observations pancreatic PAF levels chronic phase obstructive pancreatitis duct ligation inhibition action PAF specific receptor antagonism attenuation pancreatic lesions chronic administration PAF decreased pancreatic regeneration exocrine function consistent pivotal role PAF late-phase inflammatory mediator chronic pancreatitis rats